LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

Search

Axsome Therapeutics Inc

Închisă

SectorSănătate

148.72 0.62

Rezumat

Modificarea prețului

24h

Curent

Minim

148.35

Maxim

150.06

Indicatori cheie

By Trading Economics

Venit

744K

-47M

Vânzări

21M

171M

EPS

-0.94

Marjă de profit

-27.621

Angajați

816

EBITDA

-7.7M

-44M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+17.44% upside

Statistici piață

By TradingEconomics

Capitalizare de piață

792M

7.5B

Deschiderea anterioară

148.1

Închiderea anterioară

148.72

Sentimentul știrilor

By Acuity

15%

85%

16 / 374 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Weak Bearish Evidence

Axsome Therapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

5 dec. 2025, 21:08 UTC

Achiziții, Fuziuni, Preluări

Meta Platforms Buys AI-Device Maker Limitless

5 dec. 2025, 19:39 UTC

Principalele dinamici ale pieței

Parsons' FAA Bid Loss Clouds Outlook After Rocky Year for Contractors

5 dec. 2025, 19:17 UTC

Achiziții, Fuziuni, Preluări

Constellation Energy Agrees to Divest Assets to Finalize Calpine Deal

5 dec. 2025, 21:59 UTC

Achiziții, Fuziuni, Preluări

Netflix's Megadeal Will Need the Trump Administration's Blessing -- Update

5 dec. 2025, 21:50 UTC

Market Talk
Câștiguri

Financial Services Roundup: Market Talk

5 dec. 2025, 21:50 UTC

Achiziții, Fuziuni, Preluări

The Netflix and Warner Bros. Deal Is Far From a Sure Thing -- Barrons.com

5 dec. 2025, 21:36 UTC

Market Talk

Return of Shipping to Red Sea a Step Closer, Xeneta Says -- Market Talk

5 dec. 2025, 21:35 UTC

Achiziții, Fuziuni, Preluări

The Netflix-Warner Bros. Deal Has a Wildcard. How Paramount Could Still Win. -- Barrons.com

5 dec. 2025, 21:26 UTC

Achiziții, Fuziuni, Preluări

Warner Bros. Discovery and Netflix Enter Exclusive Deal Negotiations -- 7th Update

5 dec. 2025, 21:12 UTC

Market Talk

Natural Gas Surge 9% This Week on Strong Flow of Exports -- Market Talk

5 dec. 2025, 21:03 UTC

Market Talk
Câștiguri

Bank of Montreal Logs Solid Quarter, Though Some Unease Remains -- Market Talk

5 dec. 2025, 21:01 UTC

Market Talk

Oil Caps Positive Week on Geopolitical Turmoil -- Market Talk

5 dec. 2025, 20:43 UTC

Achiziții, Fuziuni, Preluări

Limitless CEO Siroker: Will No Longer Sell Pendant to New Customers

5 dec. 2025, 20:43 UTC

Achiziții, Fuziuni, Preluări

Limitless CEO Siroker: Existing Pendant Customers to Be Supported for at Least Another Year

5 dec. 2025, 20:42 UTC

Achiziții, Fuziuni, Preluări

Limitless CEO Dan Siroker: Limitless Has Been Acquired by Meta >META

5 dec. 2025, 20:01 UTC

Achiziții, Fuziuni, Preluări

Netflix Landed a Big Deal. Now it Could Have a Big Fight. -- WSJ

5 dec. 2025, 19:44 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

5 dec. 2025, 19:44 UTC

Market Talk

Canada Dollar Gains Nearly 1% on Jobs Data, Rate Outlook -- Market Talk

5 dec. 2025, 19:39 UTC

Market Talk

Silver Climbs to a New Record High -- Market Talk

5 dec. 2025, 19:31 UTC

Achiziții, Fuziuni, Preluări

Netflix Stock Falls. Wall Street Is Worried About Warner Deal's High Price and Debt. -- Barrons.com

5 dec. 2025, 18:30 UTC

Market Talk

Canada Jobless Rate Can Fall More Before Labor Slack Disappears -- Market Talk

5 dec. 2025, 18:28 UTC

Achiziții, Fuziuni, Preluări

Netflix Stock Falls. Wall Street Is Worried About Warner Deal's High Price and Debt. -- Barrons.com

5 dec. 2025, 18:24 UTC

Achiziții, Fuziuni, Preluări

AMC and IMAX Stocks Drop. Roku Rises. How the Netflix-Warner Bros. Deal Could Shake Up Entertainment. -- Barrons.com

5 dec. 2025, 18:20 UTC

Market Talk

Baker Hughes Reports Higher U.S. Rig Count -- Market Talk

5 dec. 2025, 18:11 UTC

Market Talk

The Tale of Two Canadian Employment Indicators -- Market Talk

5 dec. 2025, 17:48 UTC

Market Talk

Canadian Youth Unemployment Rate Cools -- Market Talk

5 dec. 2025, 17:44 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Global Equities Roundup: Market Talk

5 dec. 2025, 17:44 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Correction to Imax Market Talk

5 dec. 2025, 17:35 UTC

Market Talk

Canada Jobs Data Doesn't Jive With Trade Uncertainty, Indicators -- Market Talk

5 dec. 2025, 17:25 UTC

Market Talk

Canadian Jobs Numbers May Support Rates Hikes Next Year -- Market Talk

Comparație

Modificare preț

Axsome Therapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

17.44% sus

Prognoză pe 12 luni

Medie 175.25 USD  17.44%

Maxim 202 USD

Minim 148 USD

În baza a 15 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruAxsome Therapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

15 ratings

15

Cumpărare

0

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

107.24 / 112.29Suport & Rezistență

Termen scurt

Weak Bearish Evidence

Termen mediu

Neutral Evidence

Termen lung

Strong Bullish Evidence

Sentiment

By Acuity

16 / 374 Clasament în Sănătate

Sentimentul știrilor

Evidențe foarte puternice de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Axsome Therapeutics Inc

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
help-icon Live chat